The Shoda Lab at Cincinnati Children’s is working to identify the key genes and genetic regulatory mechanisms that predispose patients to eosinophilic conditions, especially eosinophilic gastrointestinal diseases (EGID). Through translational and clinical research, the Shoda Lab hopes to improve the understanding, diagnosis, and treatment of these eosinophilic conditions.
As both a clinician and a researcher, Tetsuo Shoda, MD, PhD uses his dual physician-scientist role to help bridge the gap between the research lab and clinical settings.
Our team recognizes the large clinical burden brought on by eosinophilic diseases, such as severe eosinophilic asthma and EGID. We see the complexity of the disease pathogenesis as both intriguing and challenging.
The mission of the Shoda Lab is to improve the lives of patients with severe allergies and their families by accelerating translational research.
In addition, the Shoda Lab hopes to create more-precise medicine for better treatment of severe allergies, like eosinophilic conditions, through the comprehensive, personalized characterization of the genetic, molecular and clinical features of these severe allergies.